{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T09:51:18Z","timestamp":1777197078451,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,3,7]],"date-time":"2015-03-07T00:00:00Z","timestamp":1425686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40264-015-0277-9","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T18:50:35Z","timestamp":1425667835000},"page":"395-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeted Spontaneous Reporting of Suspected Renal Toxicity in Patients Undergoing Highly Active Anti-Retroviral Therapy in Two Public Health Facilities in Uganda"],"prefix":"10.1007","volume":"38","author":[{"given":"Helen","family":"Ndagije","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Nambasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Namagala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huldah","family":"Nassali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Kajungu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Sematiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sten","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,7]]},"reference":[{"key":"277_CR1","unstructured":"Government of Uganda, Ministry of Health. 2010. Health sector strategic plan III 2010\/11-2014\/15. http:\/\/www.health.go.ug\/docs\/HSSP_III_2010.pdf . Accessed 28 Oct 2014."},{"key":"277_CR2","unstructured":"Government of Uganda, Ministry of Health, December 2008. Access to and use of medicines by households in Uganda: report of a survey conducted 2008. http:\/\/www.afro.who.int\/en\/downloads\/doc_download\/5722-uganda-access-to-and-use-of-medecines-by-households.html . Accessed 26 Dec 2014."},{"key":"277_CR3","unstructured":"WHO Collaborating Centre for International Drug Monitoring, Reporting trends. Uppsala, Sweden. Updated 2014 Nov 25. http:\/\/who-umc.org\/graphics\/28351.gif . Accessed 30 Dec 2014."},{"issue":"5","key":"277_CR4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409\u201319.","journal-title":"Drug Inf J."},{"issue":"12","key":"277_CR5","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/BF03262002","volume":"35","author":"L Aagaard","year":"2012","unstructured":"Aagaard L, Strandell J, Melskens L, Petersen PSG, Hansen EH. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase\u2122. Drug Saf. 2012;35(12):1171\u201382.","journal-title":"Drug Saf"},{"issue":"11","key":"277_CR6","doi-asserted-by":"crossref","first-page":"e005869","DOI":"10.1136\/bmjopen-2014-005869","volume":"4","author":"R Kiguba","year":"2014","unstructured":"Kiguba R, Karamagi C, Waako P, Ndagije HB, Bird SM. Recognition and reporting of suspected adverse drug reactions by surveyed healthcare professionals in Uganda: key determinants. BMJ Open. 2014;4(11):e005869.","journal-title":"BMJ Open"},{"key":"277_CR7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz B, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200\u20135.","journal-title":"JAMA"},{"issue":"2","key":"277_CR8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0002-9343(00)00451-4","volume":"109","author":"JH Gurwitz","year":"2000","unstructured":"Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109(2):87\u201394.","journal-title":"Am J Med"},{"issue":"5","key":"277_CR9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"key":"277_CR10","unstructured":"WHO Collaborating Centre for International Drug Monitoring, VigiLyze, Search and Analyse VigiBase, The WHO Global Database of Individual Case Safety Reports (ICSRs). Uppsala, Sweden. Updated 2014 Dec 11. https:\/\/vigilyze.who-umc.org . Accessed 30 Dec 2014."},{"key":"277_CR11","unstructured":"Uganda Bureau of Statistics, 2014 Census Population [Internet]. Kampala; p. 6. Available from: http:\/\/unstats.un.org\/unsd\/demographic\/sources\/census\/2010_PHC\/Uganda\/UGA-2014-11.pdf . Accessed 26 Dec 2014."},{"key":"277_CR12","unstructured":"Strengthening Pharmaceutical Systems (SPS) Program. Safety of medicine in sub-Saharan Africa: assessment of pharma-covigilance systems and their performance. Submitted to the US Agency for International Development by the Strengthening Pharmaceutical Systems (SPS) Program. Arlington: Management Sciences for Health; 2011. http:\/\/apps.who.int\/medicinedocs\/documents\/s19152en\/s19152en.pdf . Accessed 26 Dec 2014."},{"key":"277_CR13","unstructured":"Uganda STD\/AIDS Control Programme. HIV and AIDS Uganda country progress report; 2013. Kampala; 2014. http:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/UGA_narrative_report2014.pdf . Accessed 26 Dec 2014."},{"issue":"2","key":"277_CR14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","volume":"36","author":"SN Pal","year":"2013","unstructured":"Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75\u201381.","journal-title":"Drug Saf"},{"issue":"1","key":"277_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-6405-9-19","volume":"9","author":"AC Chua","year":"2012","unstructured":"Chua AC, Llorin RM, Lai K, Cavailler P, Law H. Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort. AIDS Res Ther. 2012;9(1):19.","journal-title":"AIDS Res Ther."},{"key":"277_CR16","first-page":"354908","volume":"2011","author":"B Fernandez-Fernandez","year":"2011","unstructured":"Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Ni\u00f1o MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.","journal-title":"AIDS Res Treat."},{"issue":"5","key":"277_CR17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"RD Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496\u2013505.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"277_CR18","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/QAD.0b013e328307a051","volume":"22","author":"LB Mulenga","year":"2008","unstructured":"Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, et al. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS. 2008;22(14):1821\u20137.","journal-title":"AIDS."},{"issue":"11","key":"277_CR19","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1128\/AAC.00437-06","volume":"50","author":"F Vidal","year":"2006","unstructured":"Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, S\u00e1nchez De La Rosa R, et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother. 2006;50(11):3824\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"277_CR20","unstructured":"Ministry of Health, Uganda. The Integrated National Guidelines on Antiretroviral Therapy, Prevention of mother to child transmission of HIV and infant & young child feeding. 1st ed. Kampala; 2011. http:\/\/www.emtct-iatt.org\/wp-content\/uploads\/2014\/05\/GL_Integrated-National-Guidelines-on-ART-PMTCT-and-IYCF-June-2011-MOH-Uganda_0.pdf . Accessed 16 Feb 2015."},{"issue":"2","key":"277_CR21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/apc.2007.0052","volume":"22","author":"SK Gupta","year":"2008","unstructured":"Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22(2):99\u2013103.","journal-title":"AIDS Patient Care STDS."},{"key":"277_CR22","first-page":"379","volume":"5","author":"FT Romo","year":"2014","unstructured":"Romo FT, Aziz M, Livak B, Huesgen E, Colton B, et al. Renal function recovery and HIV viral suppression following tenofovir discontinuation for renal impairment. J AIDS Clin Res. 2014;5:379. doi: 10.4172\/2155-6113.1000379 .","journal-title":"J AIDS Clin Res"},{"issue":"1","key":"277_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00002018-199819010-00001","volume":"19","author":"S Olsson","year":"1998","unstructured":"Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19(1):1\u201310.","journal-title":"Drug Saf"},{"issue":"2","key":"277_CR24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"277_CR25","unstructured":"Europeans Medicines Agency. Tenofovir summary of product characteristics. 2002. p. 1\u2013183. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000419\/WC500051737.pdf . Accessed 8 Jan 2015."},{"issue":"5","key":"277_CR26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","volume":"57","author":"AM Hall","year":"2011","unstructured":"Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57(5):773\u201380.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"277_CR27","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","volume":"26","author":"R Scherzer","year":"2012","unstructured":"Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867\u201375.","journal-title":"AIDS."},{"issue":"1","key":"277_CR28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.biopha.2007.04.008","volume":"62","author":"G Madeddu","year":"2008","unstructured":"Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, et al. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother. 2008;62(1):6\u201311.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"277_CR29","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/01.qai.0000138983.45235.02","volume":"37","author":"R Jones","year":"2004","unstructured":"Jones R, Stebbing J, Nelson M, Moyle G, Bower M, Mandalia S, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37(4):1489\u201395.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-015-0277-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0277-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0277-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T18:50:27Z","timestamp":1566413427000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-015-0277-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["277"],"URL":"https:\/\/doi.org\/10.1007\/s40264-015-0277-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,7]]}}}